Cadence Pharmaceuticals, Inc. (CADX.W)

CADX.W on CBOE When Trading NASDAQ Global Select Market

10.32USD
9 Feb 2010
Price Change (% chg)

$0.45 (+4.55%)
Prev Close
$10.32
Open
--
Day's High
$10.35
Day's Low
$9.88
Volume
652,616
Avg. Vol
552,623
52-wk High
$12.68
52-wk Low
$5.68

CADX.W

Chart for CADX.W

About

Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing its product candidates principally for use in the hospital setting. The Company has in-licensed rights to two late stage product candidates, Acetavance a intravenous formulation of acetaminophen and Omigard... (more)

Overall

Beta: 1.61
Market Cap (Mil.): $521.67
Shares Outstanding (Mil.): 50.45
Annual Dividend: 0.00
Yield (%): NA

Financials

  CADX.W Industry Sector
P/E (TTM): -- 11.50 3.76
EPS (TTM): 40.73 -- --
ROI: -63.86 1.25 2.30
ROE: -69.34 2.09 2.82
view overview for:

Latest News about CADX.W

UPDATE 2-Cadence says FDA delays painkiller review, shares fall

* Extended action date on the painkiller is Feb 12, 2010

13 Nov 2009

BEFORE THE BELL-Cadence painkiller review delayed; shares fall

NEW YORK, Nov 13 (Reuters) - Cadence Pharmaceuticals Inc shares slid 6.3 percent to $8.95 in premarket trade on Friday after the U.S. Food and Drug Administration delayed the review date for the experimental intravenous painkiller Acetavance. For more see [ID:nBNG93849] (Reporting by Chuck Mikolajczak; Editing by James Dalgleish)

13 Nov 2009
» More CADX.W News

Competitors

  Price Change
Anesiva, Inc. (ANSV.PK) $0.05 +0.00
Paion AG (PA8G.DE) €2.40 -0.05
Cumberland Pharmaceuticals, Inc. (CPIX.OQ) $11.52 +0.11
DURECT Corporation (DRRX.OQ) $2.01 +0.06
Javelin Pharmaceuticals Inc. (JAV.A) $1.17 +0.02
Acusphere, Inc. (ACUS.PK) $0.07 0.00
Cephalon, Inc. (CEPH.OQ) $65.78 +0.78

  Earnings  vs    Estimates

view overview for: